Cargando…

The SGLT2-inhibitor dapagliflozin improves neutropenia and neutrophil dysfunction in a mouse model of the inherited metabolic disorder GSDIb

Glycogen Storage Disease type 1b (GSDIb) is a genetic disorder with long term severe complications. Accumulation of the glucose analog 1,5-anhydroglucitol-6-phosphate (1,5AG6P) in neutrophils inhibits the phosphorylation of glucose in these cells, causing neutropenia and neutrophil dysfunctions. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Resaz, Roberta, Raggi, Federica, Segalerba, Daniela, Lavarello, Chiara, Gamberucci, Alessandra, Bosco, Maria Carla, Astigiano, Simonetta, Assunto, Antonia, Melis, Daniela, D'Acierno, Mariavittoria, Veiga-da-Cunha, Maria, Petretto, Andrea, Marcolongo, Paola, Trepiccione, Francesco, Eva, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531659/ https://www.ncbi.nlm.nih.gov/pubmed/34712576 http://dx.doi.org/10.1016/j.ymgmr.2021.100813

Ejemplares similares

Bardet–Biedl syndrome: The pleiotropic role of the chaperonin‐like BBS6, 10, and 12 proteins
por: Gupta, Neha, et al.
Publicado: (2022)

Potassium depletion induces cellular conversion in the outer medullary collecting duct altering Notch signaling pathway
por: Iervolino, Anna, et al.
Publicado: (2020)

ERK1,2 Signalling Pathway along the Nephron and Its Role in Acid-base and Electrolytes Balance
por: Capolongo, Giovanna, et al.
Publicado: (2019)

Circulating exosomal microRNAs as potential biomarkers of hepatic injury and inflammation in a murine model of glycogen storage disease type 1a
por: Resaz, Roberta, et al.
Publicado: (2020)

Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation
por: Melis, Daniela, et al.
Publicado: (2015)

The autophagy inducer trehalose stimulates macropinocytosis in NF1-deficient glioblastoma cells
por: Del Bello, Barbara, et al.
Publicado: (2022)

Plasma-Derived Exosome Proteins as Novel Diagnostic and Prognostic Biomarkers in Neuroblastoma Patients
por: Morini, Martina, et al.
Publicado: (2023)

Characterization of high- and low-risk hepatocellular adenomas by magnetic resonance imaging in an animal model of glycogen storage disease type 1A
por: Resaz, Roberta, et al.
Publicado: (2019)

Exosomal MicroRNAs as Potential Biomarkers of Hepatic Injury and Kidney Disease in Glycogen Storage Disease Type Ia Patients
por: Resaz, Roberta, et al.
Publicado: (2021)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-α deficiency
por: Resaz, Roberta, et al.
Publicado: (2014)

Treatment of the Neutropenia Associated with GSD1b and G6PC3 Deficiency with SGLT2 Inhibitors
por: Veiga-da-Cunha, Maria, et al.
Publicado: (2023)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Fructose, Glucocorticoids and Adipose Tissue: Implications for the Metabolic Syndrome
por: Legeza, Balázs, et al.
Publicado: (2017)

Hazelnut extract-loaded nanostructured lipid carriers and evaluation of their antioxidant properties
por: Emanet, Melis, et al.
Publicado: (2022)

SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia
por: Diederich, Jennifer, et al.
Publicado: (2023)

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
por: Ott, Christian, et al.
Publicado: (2017)

Sumac (Rhus coriaria) Extract-Loaded Polymeric Nanosheets Efficiently Protect Human Dermal Fibroblasts from Oxidative Stress
por: Emanet, Melis, et al.
Publicado: (2022)

A scale space approach for unsupervised feature selection in mass spectra classification for ovarian cancer detection
por: Ceccarelli, Michele, et al.
Publicado: (2009)

GALT Protein Database, a Bioinformatics Resource for the Management and Analysis of Structural Features of a Galactosemia-related Protein and Its Mutants
por: d’Acierno, Antonio, et al.
Publicado: (2009)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
por: Karg, M. V., et al.
Publicado: (2018)

SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes
por: Hodrea, Judit, et al.
Publicado: (2022)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
por: Dobner, Stephan, et al.
Publicado: (2022)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

An extensible six-step methodology to automatically generate fuzzy DSSs for diagnostic applications
por: d'Acierno, Antonio, et al.
Publicado: (2013)

Successful use of empagliflozin to treat neutropenia in two G6PC3‐deficient children: Impact of a mutation in SGLT5
por: Boulanger, Cécile, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE(−/−) Mice
por: Leng, Weiling, et al.
Publicado: (2016)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen, Thiquynhnga, et al.
Publicado: (2020)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
por: Nassif, Michael E., et al.
Publicado: (2021)

The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure
por: Berezin, Alexander A., et al.
Publicado: (2022)

Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
por: op den Kamp, Yvo J.M., et al.
Publicado: (2022)

Antihypertensive, cardio- and neuro-protective effects of Tenebrio molitor (Coleoptera: Tenebrionidae) defatted larvae in spontaneously hypertensive rats
por: Pessina, Federica, et al.
Publicado: (2020)

Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy
por: Erdogan, Mumin Alper, et al.
Publicado: (2018)

The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
por: Ohara, Ken, et al.
Publicado: (2020)

The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis
por: Wallenius, Kristina, et al.
Publicado: (2022)

Exercise Augments the Effect of SGLT2 Inhibitor Dapagliflozin on Experimentally Induced Diabetic Cardiomyopathy, Possible Underlying Mechanisms
por: Eldesoqui, Mamdouh, et al.
Publicado: (2022)

Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF
por: Fu, Qianyu, et al.
Publicado: (2023)

Artificial Neural Networks for Forecasting Passenger Flows on Metro Lines
por: Gallo, Mariano, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2sb27rt8p3q7p7cpjnqg3q4e3m